CG Oncology (CGON) Operating Expenses (2023 - 2026)

CG Oncology has reported Operating Expenses for 4 years, with the latest figure at $67.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 59.67% year-over-year to $67.5 million; the trailing twelve-month figure through Mar 2026 stood at $220.0 million (up 62.91% YoY), and the FY2025 full-year result was $194.8 million, up 68.23% from the prior year.
• Operating Expenses for Q1 2026 stood at $67.5 million, up from $51.0 million in the prior quarter.
• The five-year high for Operating Expenses was $67.5 million in Q1 2026, with the low at $9.9 million in Q1 2023.
• Historically, Operating Expenses has averaged $33.4 million across 4 years, with a median of $28.3 million in 2024.
• Annual changes were most pronounced in 2024 — Operating Expenses surged 131.95% — and 2025, when it soared 32.51%.
• CG Oncology's Operating Expenses stood at $19.4 million in 2023, then jumped by 98.93% to $38.5 million in 2024, then surged by 32.51% to $51.0 million in 2025, then jumped by 32.24% to $67.5 million in 2026.
• The last three Operating Expenses figures came in at $67.5 million (Q1 2026), $51.0 million (Q4 2025), and $52.8 million (Q3 2025), per Business Quant data.